NEW YORK (GenomeWeb News) – Novozymes and ProMetic Life Sciences today announced a co-marketing alliance for an albumin purification technology based on a synthetic-ligand affinity adsorbent developed by ProMetic's UK subsidiary, ProMetic BioSciences.
The purification technology was designed for the rapid and cost-effective development of Novozymes' albufuse albumin-fusion molecules, the firms said.
Under terms of the alliance, the firms will jointly promote the use of the new adsorbent, marketed under the trade-name AlbuPure, as a platform approach for the purification of albumin and albumin-fusion proteins. ProMetic will serve as exclusive manufacturer and supplier of AlbuPure, but both parties will retain ownership of their respective technologies and both Novozymes and ProMetic will have the right to market AlbuPure.
"This alliance with ProMetic will enable us to expand the technology package offered to our clients to include both protein expression and protein purification technology for albumin-fusion proteins," Dave Mead, business development director of Novozymes Biopharma, said in a statement. "The availability of a robust affinity capture step, fully supported by Novozymes Biopharma and ProMetic, will provide significant advantages to our clients, including reduced development times and simplified high-yield manufacturing processes."
Further terms of the alliance were not disclosed.